Alicia E Meuret1, Thomas Ritz2, Frank H Wilhelm3, Walton T Roth4, David Rosenfield2. 1. Department of Psychology, Southern Methodist University, Dallas, Texas. Electronic address: ameuret@smu.edu. 2. Department of Psychology, Southern Methodist University, Dallas, Texas. 3. Department of Psychology, University of Salzburg, Salzburg, Austria. 4. Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California.
Abstract
BACKGROUND: Previous research has shown that hypoventilation therapy reduces panic symptoms in part by increasing basal partial pressure of carbon dioxide (PCO2) levels. We tested an additional pathway by which hypoventilation therapy could exert its therapeutic effects: through repeated interoceptive exposure to sensations of dyspnea. METHODS: A total of 35 patients with panic disorder were trained to perform exercises to raise their end-tidal PCO2 levels using a portable capnometry device. Anxiety, dyspnea, end-tidal PCO2, and respiratory rate were assessed during each exercise across 4 weeks of training. Mixed-model analysis examined whether within-exercise levels of dyspnea were predictive of reduction of panicogenic cognitions. RESULTS: As expected, within-exercise anxiety and respiratory rate decreased over time. Unexpectedly, PCO2 dropped significantly from the beginning to the end of exercise, with these drops becoming progressively smaller across weeks. Dyspnea increased and remained consistently above basal levels across weeks. As hypothesized, greater dyspnea was related to significantly lower panicogenic cognitions over time even after controlling for anxiety and PCO2. Additional exploratory analyses showed that within-exercise increases in dyspnea were related to within-exercise increases in anxiety but were not related to within-exercise increases in PCO2. CONCLUSIONS: In support of the interoceptive exposure model, we found that greater dyspnea during hypoventilation exercises resulted in lower panicogenic cognitions even after the effect of PCO2 was taken into account. The findings offer an additional important target in panic treatment.
BACKGROUND: Previous research has shown that hypoventilation therapy reduces panic symptoms in part by increasing basal partial pressure of carbon dioxide (PCO2) levels. We tested an additional pathway by which hypoventilation therapy could exert its therapeutic effects: through repeated interoceptive exposure to sensations of dyspnea. METHODS: A total of 35 patients with panic disorder were trained to perform exercises to raise their end-tidal PCO2 levels using a portable capnometry device. Anxiety, dyspnea, end-tidal PCO2, and respiratory rate were assessed during each exercise across 4 weeks of training. Mixed-model analysis examined whether within-exercise levels of dyspnea were predictive of reduction of panicogenic cognitions. RESULTS: As expected, within-exercise anxiety and respiratory rate decreased over time. Unexpectedly, PCO2 dropped significantly from the beginning to the end of exercise, with these drops becoming progressively smaller across weeks. Dyspnea increased and remained consistently above basal levels across weeks. As hypothesized, greater dyspnea was related to significantly lower panicogenic cognitions over time even after controlling for anxiety and PCO2. Additional exploratory analyses showed that within-exercise increases in dyspnea were related to within-exercise increases in anxiety but were not related to within-exercise increases in PCO2. CONCLUSIONS: In support of the interoceptive exposure model, we found that greater dyspnea during hypoventilation exercises resulted in lower panicogenic cognitions even after the effect of PCO2 was taken into account. The findings offer an additional important target in panic treatment.
Authors: Alicia E Meuret; Kamila S White; Thomas Ritz; Walton T Roth; Stefan G Hofmann; Timothy A Brown Journal: J Psychiatr Res Date: 2005-11-15 Impact factor: 4.791
Authors: M K Shear; T A Brown; D H Barlow; R Money; D E Sholomskas; S W Woods; J M Gorman; L A Papp Journal: Am J Psychiatry Date: 1997-11 Impact factor: 18.112
Authors: Alicia E Meuret; David Rosenfield; Lavanya Bhaskara; Richard Auchus; Israel Liberzon; Thomas Ritz; James L Abelson Journal: Psychoneuroendocrinology Date: 2016-09-15 Impact factor: 4.905
Authors: Jasper A J Smits; David Rosenfield; Michael W Otto; Luana Marques; Michelle L Davis; Alicia E Meuret; Naomi M Simon; Mark H Pollack; Stefan G Hofmann Journal: J Psychiatr Res Date: 2013-07-16 Impact factor: 4.791
Authors: Adam E Ziemann; Jason E Allen; Nader S Dahdaleh; Iuliia I Drebot; Matthew W Coryell; Amanda M Wunsch; Cynthia M Lynch; Frank M Faraci; Matthew A Howard; Michael J Welsh; John A Wemmie Journal: Cell Date: 2009-11-25 Impact factor: 41.582
Authors: Sahib S Khalsa; Justin S Feinstein; Wei Li; Jamie D Feusner; Ralph Adolphs; Rene Hurlemann Journal: J Neurosci Date: 2016-03-23 Impact factor: 6.167
Authors: Sahib S Khalsa; Ralph Adolphs; Oliver G Cameron; Hugo D Critchley; Paul W Davenport; Justin S Feinstein; Jamie D Feusner; Sarah N Garfinkel; Richard D Lane; Wolf E Mehling; Alicia E Meuret; Charles B Nemeroff; Stephen Oppenheimer; Frederike H Petzschner; Olga Pollatos; Jamie L Rhudy; Lawrence P Schramm; W Kyle Simmons; Murray B Stein; Klaas E Stephan; Omer Van den Bergh; Ilse Van Diest; Andreas von Leupoldt; Martin P Paulus Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-12-28